KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 43,707 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par acquired 43,707 shares of the stock in a transaction dated Thursday, January 30th. The stock was acquired at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the purchase, the insider now directly owns 4,986,480 shares in the company, valued at approximately $43,681,564.80. This trade represents a 0.88 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $9.22 per share, for a total transaction of $134,261.64.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $9.22 on Tuesday. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $16.88. The company has a 50 day simple moving average of $8.81 and a two-hundred day simple moving average of $10.81. The firm has a market cap of $455.65 million, a P/E ratio of -2.53 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. On average, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research note on Friday. They issued an “outperform” rating and a $19.00 price objective on the stock. TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Finally, Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $23.80.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Suvretta Capital Management LLC grew its holdings in shares of KalVista Pharmaceuticals by 0.5% in the third quarter. Suvretta Capital Management LLC now owns 4,212,005 shares of the specialty pharmaceutical company’s stock valued at $48,775,000 after purchasing an additional 20,000 shares in the last quarter. Vestal Point Capital LP lifted its position in KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after buying an additional 1,700,000 shares during the last quarter. State Street Corp lifted its position in KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after buying an additional 515,179 shares during the last quarter. Emerald Advisers LLC lifted its position in KalVista Pharmaceuticals by 29.8% in the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after buying an additional 192,091 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in KalVista Pharmaceuticals by 3.1% in the third quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company’s stock worth $9,624,000 after buying an additional 24,713 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).